GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyprotex PLC (LSE:CRX) » Definitions » YoY EPS Growth

Cyprotex (LSE:CRX) YoY EPS Growth : 887.50% (As of Jun. 2016)


View and export this data going back to 2002. Start your Free Trial

What is Cyprotex YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Cyprotex's YoY EPS Growth for the quarter that ended in Jun. 2016 was 887.50%.

Cyprotex's Earnings per Share (Diluted) for the six months ended in Jun. 2016 was £0.13.


Cyprotex YoY EPS Growth Historical Data

The historical data trend for Cyprotex's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyprotex YoY EPS Growth Chart

Cyprotex Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.81 -76.92 -500.00 -416.67 -55.91

Cyprotex Semi-Annual Data
Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -238.46 -242.86 11.11 -63.10 887.50

Cyprotex YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Cyprotex's YoY EPS Growth for the fiscal year that ended in Dec. 2015 is calculated as:

YoY EPS Growth (A: Dec. 2015 )
=(Earnings per Share (Diluted) (A: Dec. 2015 )-Earnings per Share (Diluted) (A: Dec. 2014 ))/ | Earnings per Share (Diluted) (A: Dec. 2014 ) |
=(-0.29--0.186)/ | -0.186 |
=-55.91 %

Cyprotex's YoY EPS Growth for the quarter that ended in Jun. 2016 is calculated as:

YoY EPS Growth (Q: Jun. 2016 )
=(Earnings per Share (Diluted) (Q: Jun. 2016 )-Earnings per Share (Diluted) (Q: Jun. 2015 )) / | Earnings per Share (Diluted) (Q: Jun. 2015 )) |
=(0.126--0.016)/ | -0.016 |
=887.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyprotex YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Cyprotex's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyprotex (LSE:CRX) Business Description

Traded in Other Exchanges
N/A
Address
Cyprotex PLC was incorporated on October 25, 2001. The Company together with its subsidiaries, provides in vitro and in silico ADMET and PK (absorption, distribution, metabolism, excretion, toxicity and pharmacokinetics) information to a number of different industries including the Pharmaceutical, Biotechnology, Cosmetic, Personal Care, Agrochemical, Chemical Industries and Academia. It provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. The Company operates in North America, Mainland Europe and United Kingdom.

Cyprotex (LSE:CRX) Headlines

No Headlines